Robert Janssen - Nov 16, 2021 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)

Role
Senior Vice President
Signature
/s/ Robert Janssen
Stock symbol
DVAX
Transactions as of
Nov 16, 2021
Transactions value $
-$593,701
Form type
4
Date filed
11/18/2021, 04:06 PM
Previous filing
Sep 3, 2021
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DVAX Common Stock Options Exercise $377K +36K +434.68% $10.47 44.3K Nov 16, 2021 Direct
transaction DVAX Common Stock Sale -$617K -36K -81.3% $17.16 8.28K Nov 16, 2021 Direct F1
transaction DVAX Common Stock Options Exercise $559K +53.4K +645.61% $10.47 61.7K Nov 17, 2021 Direct
transaction DVAX Common Stock Sale -$912K -53.4K -86.59% $17.07 8.28K Nov 17, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DVAX Stock Option (Right to Buy) Options Exercise -36K -34.89% 67.1K Nov 16, 2021 Common Stock 36K $10.47 Direct F3, F4
transaction DVAX Stock Option (Right to Buy) Options Exercise -53.4K -79.6% 13.7K Nov 17, 2021 Common Stock 53.4K $10.47 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $17.01 to $17.27; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
F2 This transaction was executed in multiple trades at prices ranging from $16.92 to $17.30; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
F3 This option grant will vest over three (3) years with one-third (1/3) of the shares subject to the option vesting twelve months after the grant date, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter.
F4 Not applicable